Poolbeg Pharma PLC Net Assets
Poolbeg Pharma PLC net assets. Based on the latest financial reports, Poolbeg Pharma PLC (POLB) has net assets worth GBX8.60 Million GBX (≈ $1.05K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX9.94 Million ≈ $1.21K USD) and total liabilities (GBX1.34 Million ≈ $163.16 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore POLB year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX8.60 Million |
| % of Total Assets | 86.51% |
| Annual Growth Rate | -21.44% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 10.15 |
Net Assets of Poolbeg Pharma PLC (2021–2025)
Net assets of Poolbeg Pharma PLC from 2021 to 2025. This chart illustrates how Poolbeg Pharma PLC's net assets have evolved over time, based on quarterly financial data. See POLB net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Poolbeg Pharma PLC (2021–2025)
The table below shows the annual net assets of Poolbeg Pharma PLC from 2021 to 2025. For live market cap and overall valuation, see POLB market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | GBX8.60 Million ≈ $1.05K |
-7.25% |
| 2024-12-31 | GBX9.27 Million ≈ $1.13K |
-35.79% |
| 2023-12-31 | GBX14.44 Million ≈ $1.76K |
-21.18% |
| 2022-12-31 | GBX18.32 Million ≈ $2.23K |
-18.85% |
| 2021-12-31 | GBX22.58 Million ≈ $2.75K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Poolbeg Pharma PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1864700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Poolbeg Pharma PLC Net Assets Breakdown (December 2025)
Poolbeg Pharma PLC net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX139.00K | 1.62% |
| Other Comprehensive Income | GBX1.91 Million | 22.17% |
| Other Components | GBX27.54 Million | 320.17% |
| Total Equity | GBX8.60 Million | 100.00% |
Poolbeg Pharma PLC Competitors by Market Cap
The table below lists competitors of Poolbeg Pharma PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LeoNovus Inc
V:LTV
|
$604.78K |
|
IRWIN NATURALS INC.
F:97X
|
$606.63K |
|
Pioneering Technology Corp
V:PTE
|
$608.10K |
|
EPE Special Opportunities Limited
LSE:ESO
|
$608.68K |
|
Starwood European Real Estate Finance Ltd
LSE:SWEF
|
$603.58K |
|
Waseco Resources Inc.
V:WRI
|
$603.03K |
|
Volvere PLC
LSE:VLE
|
$599.51K |
|
Vitality Products Inc
V:VPI
|
$599.13K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Poolbeg Pharma PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,273,000 to 8,601,000, a change of -672,000 (-7.2%).
- Net loss of 5,695,000 reduced equity.
- New share issuances of 4,477,000 increased equity.
- Other comprehensive income decreased equity by 909,000.
- Other factors increased equity by 1,455,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-5.70 Million | -66.21% |
| Share Issuances | GBX4.48 Million | +52.05% |
| Other Comprehensive Income | GBX-909.00K | -10.57% |
| Other Changes | GBX1.46 Million | +16.92% |
| Total Change | GBX- | -7.25% |
Book Value vs Market Value Analysis
This analysis compares Poolbeg Pharma PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 455.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 143.93x to 455.44x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | GBX0.05 | GBX6.50 | x |
| 2022-12-31 | GBX0.04 | GBX6.50 | x |
| 2023-12-31 | GBX0.03 | GBX6.50 | x |
| 2024-12-31 | GBX0.02 | GBX6.50 | x |
| 2025-12-31 | GBX0.01 | GBX6.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Poolbeg Pharma PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -66.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.16x
- Recent ROE (-66.21%) is below the historical average (-38.36%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -10.35% | 0.00% | 0.00x | 1.02x | GBX-4.59 Million |
| 2022 | -25.57% | 0.00% | 0.00x | 1.05x | GBX-6.52 Million |
| 2023 | -27.22% | 0.00% | 0.00x | 1.07x | GBX-5.38 Million |
| 2024 | -62.44% | 0.00% | 0.00x | 1.11x | GBX-6.72 Million |
| 2025 | -66.21% | 0.00% | 0.00x | 1.16x | GBX-6.56 Million |
Industry Comparison
This section compares Poolbeg Pharma PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $8,729,939
- Average return on equity (ROE) among peers: -88.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Poolbeg Pharma PLC (POLB) | GBX8.60 Million | -10.35% | 0.16x | $603.77K |
| 4BASEBIO UK SOCIETAS (4BB) | $26.38 Million | -46.75% | 0.70x | $998.55K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $96.80K |
| Arecor Therapeutics PLC (AREC) | $5.35 Million | -191.36% | 0.63x | $379.00K |
| Avacta Group PLC (AVCT) | $29.89 Million | -21.30% | 0.06x | $3.22 Million |
| BSF Enterprise Plc (BSFA) | $3.19 Million | -52.42% | 0.10x | $14.06K |
| Bioventix (BVXP) | $8.21 Million | 42.58% | 0.07x | $1.27 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $6.63K | -327.34% | 1.48x | $53.05K |
| CRISM Therapeutics Corporation (CRTX) | $20.72 Million | -6.57% | 0.02x | $84.30K |
| Fusion Antibodies PLC (FAB) | $669.00K | -256.05% | 0.98x | $82.97K |
| Faron Pharmaceuticals Oy (FARN) | $-15.16 Million | 0.00% | 0.00x | $436.55K |
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; … Read more